Display options
Cite
Hinsch A, Blessin NC, Simon R, et al. Expression of the immune checkpoint receptor TIGIT in seminoma. Oncol Lett. 2019;18(2):1497-1502doi: 10.3892/ol.2019.10428.
Hinsch, A., Blessin, N. C., Simon, R., Kluth, M., Fischer, K., Hube-Magg, C., Li, W., Makrypidi-Fraune, G., Wellge, B., Mandelkow, T., Debatin, N. F., Höflmayer, D., Lennartz, M., Sauter, G., Izbicki, J. R., Minner, S., Büscheck, F., Uhlig, R., Dum, D., Krech, T., Luebke, A. M., Wittmer, C., Jacobsen, F., Burandt, E., Steurer, S., & Wilczak, W. (2019). Expression of the immune checkpoint receptor TIGIT in seminoma. Oncology letters, 18(2), 1497-1502. https://doi.org/10.3892/ol.2019.10428
Hinsch, Andrea, et al. "Expression of the immune checkpoint receptor TIGIT in seminoma." Oncology letters vol. 18,2 (2019): 1497-1502. doi: https://doi.org/10.3892/ol.2019.10428
Hinsch A, Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Li W, Makrypidi-Fraune G, Wellge B, Mandelkow T, Debatin NF, Höflmayer D, Lennartz M, Sauter G, Izbicki JR, Minner S, Büscheck F, Uhlig R, Dum D, Krech T, Luebke AM, Wittmer C, Jacobsen F, Burandt E, Steurer S, Wilczak W. Expression of the immune checkpoint receptor TIGIT in seminoma. Oncol Lett. 2019 Aug;18(2):1497-1502. doi: 10.3892/ol.2019.10428. Epub 2019 May 31. PMID: 31423216; PMCID: PMC6607271.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2019 Aug;18(2):1497-1502. doi: 10.3892/ol.2019.10428. Epub 2019 May 31.

Expression of the immune checkpoint receptor TIGIT in seminoma.

Oncology letters

Andrea Hinsch, Niclas C Blessin, Ronald Simon, Martina Kluth, Kristine Fischer, Claudia Hube-Magg, Wenchao Li, Georgia Makrypidi-Fraune, Björn Wellge, Tim Mandelkow, Nicolaus F Debatin, Doris Höflmayer, Maximilian Lennartz, Guido Sauter, Jakob R Izbicki, Sarah Minner, Franziska Büscheck, Ria Uhlig, David Dum, Till Krech, Andreas M Luebke, Corinna Wittmer, Frank Jacobsen, Eike Burandt, Stefan Steurer, Waldemar Wilczak

Affiliations

  1. Department of Pathology, University Medical Center Hamburg-Eppendorf, D-20246 Hamburg, Germany.
  2. ONCOdianova GmbH, D-20354 Hamburg, Germany.
  3. Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, D-20246 Hamburg, Germany.

PMID: 31423216 PMCID: PMC6607271 DOI: 10.3892/ol.2019.10428

Abstract

A characteristic feature of testicular seminoma is the abundance of immune cells in the tumor microenvironment, raising the possibility that immune checkpoint inhibitors may serve as a therapeutic option in these types of tumors. T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory immune checkpoint receptor in analogy to PD-1, and drugs targeting TIGIT are currently being investigated in clinical trials. Little is known about the expression of these proteins in testicular seminomas. Therefore the present study performed immunohistochemical analysis to determine the relative abundance of TIGIT and PD-1 in relation to the total CD3

Keywords: Programmed Cell Death 1; T cell immunoreceptor with Ig and ITIM domains; immune checkpoint; immunotherapy; infiltrating lymphocytes; seminoma; tissue microarray

References

  1. BJU Int. 2004 Jul;94(1):74-8 - PubMed
  2. Science. 2006 Sep 29;313(5795):1960-4 - PubMed
  3. Eur Urol. 2008 Mar;53(3):478-96 - PubMed
  4. J Cancer Surviv. 2007 Mar;1(1):8-16 - PubMed
  5. Nat Immunol. 2009 Jan;10(1):48-57 - PubMed
  6. Semin Oncol. 2009 Oct;36(5):432-8 - PubMed
  7. Eur Urol. 2011 Sep;60(3):516-26 - PubMed
  8. Cancer. 2012 Feb 15;118(4):981-6 - PubMed
  9. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  10. N Engl J Med. 2013 Jul 11;369(2):122-33 - PubMed
  11. J Clin Oncol. 2014 Oct 1;32(28):3085-92 - PubMed
  12. N Engl J Med. 2014 Nov 20;371(21):2005-16 - PubMed
  13. Breast Cancer Res. 2014 Nov 29;16(6):488 - PubMed
  14. Cancer Cell. 2014 Dec 8;26(6):923-937 - PubMed
  15. N Engl J Med. 2015 Jan 22;372(4):311-9 - PubMed
  16. J Clin Invest. 2015 May;125(5):2046-58 - PubMed
  17. N Engl J Med. 2015 Jul 9;373(2):123-35 - PubMed
  18. Lancet Oncol. 2015 Aug;16(8):908-18 - PubMed
  19. J Clin Invest. 2015 Nov 2;125(11):4053-62 - PubMed
  20. Ann Oncol. 2016 Feb;27(2):300-5 - PubMed
  21. Clin Cancer Res. 2016 Jun 15;22(12):3057-66 - PubMed
  22. BMC Med. 2016 May 05;14:73 - PubMed
  23. World J Urol. 2017 Aug;35(8):1167-1175 - PubMed
  24. Trends Immunol. 2017 Jan;38(1):20-28 - PubMed
  25. Immunol Invest. 2017 Feb;46(2):172-182 - PubMed
  26. Immunol Rev. 2017 Mar;276(1):112-120 - PubMed
  27. Eur J Cancer. 2017 May;76:1-7 - PubMed
  28. Med Sci Monit. 2017 Mar 10;23:1232-1241 - PubMed
  29. Oncotarget. 2017 Mar 28;8(13):21794-21805 - PubMed
  30. Oncoimmunology. 2017 Mar 20;6(4):e1305535 - PubMed
  31. Nat Biotechnol. 2017 Jun 7;35(6):487-488 - PubMed
  32. Front Pharmacol. 2017 Aug 23;8:561 - PubMed
  33. Ann Oncol. 2018 Jan 1;29(1):209-214 - PubMed
  34. Oncotarget. 2017 Aug 25;8(41):69200-69201 - PubMed
  35. Clin Cancer Res. 2018 Feb 15;24(4):870-881 - PubMed
  36. Eur Urol. 2019 Jan;75(1):201-203 - PubMed
  37. BMC Cancer. 2018 Dec 4;18(1):1209 - PubMed
  38. Dis Markers. 2019 Jan 10;2019:5160565 - PubMed
  39. Dis Markers. 2019 May 2;2019:2532518 - PubMed
  40. Nat Med. 1998 Jul;4(7):844-7 - PubMed

Publication Types